vs
Molecular weight
4882.56 g/mol
4113.58 g/mol
Half-life
~6 days (144 hours)
~7 days (168 hours)
Research areas
Weight loss / obesityType 2 diabetesMetabolic syndromeNASH / MASH (fatty liver)Cardiovascular diseaseLipid metabolism
Weight loss / obesityType 2 diabetesCardiovascular risk reductionNASH / MASH (fatty liver)Chronic kidney diseaseAlcohol use disorder
Typical dosing
1000–12000 mcg · 1x weekly · Ongoing (titrate from 1mg to 12mg weekly over ~24 weeks)
250–2400 mcg · 1x weekly · Ongoing (titrate up over 16-20 weeks)
FDA status
Not FDA-approved. Phase 3 clinical trials underway (Eli Lilly — TRIUMPH program)
FDA-approved (Ozempic for T2D 2017, Wegovy for weight management 2021, Rybelsus oral for T2D 2019)
WADA status
Not specifically listed (covered under S0 as non-approved substance)
Not prohibited (as of 2026)
